AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03958357 — intervention group
Intervention type: DEVICE
Intervention: Advanced Gynecological Applicator configuration
Description: The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
Study NCT02859103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Description: Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
Study NCT01593124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Study NCT01593124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Study NCT01593124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Study NCT03599791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT
Description: Dymista Nasal spray suspension
Study NCT03599791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride 0.137 MG/ACTUAT
Description: AZEP Nasal spray solution
Study NCT03599791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 0.05 MG/ACTUAT
Description: Fluticasone propionate nasal spray suspension
Study NCT01469273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mutaflor® Suspension
Description: Application of Mutaflor-Suspension on 10 consecutive days.
Study NCT04684069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis syringe free in-plane
Description: Long-axis syringe-free in-plane catheter placement
Study NCT00967330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 125mg/m2 iv every 2 weeks
Study NCT00967330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: 75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
Study NCT04347720 — intervention group
Intervention type: DRUG
Intervention: Indomethacin
Description: Intravenous formulation
Study NCT04347720 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen
Description: Intravenous and oral formulations
Study NCT04684069 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Short-axis out-of-plane
Description: Short-axis out-of-plane catheter placement
Study NCT02003534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15% Brimonidine Tartrate
Description: 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
Study NCT03920254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose A
Description: See Arm description
Study NCT03920254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose B
Description: See Arm description
Study NCT03200782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral placebo (winthrop tablet)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
Study NCT03200782 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo (winthrop tablet)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
Study NCT03200782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous placebo (0.67 ml of 0.9% sodium chloride)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
Study NCT03200782 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneous placebo (0.67 ml of 0.9% sodium chloride)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
Study NCT01885390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX COUPLER
Description: The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
Study NCT03920254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose C
Description: See Arm description
Study NCT03263624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
Study NCT03263624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: tazarotene cream 0.1% once daily
Study NCT03263624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream 0.1%
Description: tazarotene cream 0.1% once daily
Study NCT01952236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web+Mobile
Description: We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
Study NCT01952236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Only
Description: A Web-based PC-delivered best practices smoking cessation intervention.
Study NCT02056795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asia-Med Special No 16 (0.30x30mm) needles
Description: Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
Study NCT02056795 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)
Description: As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
Study NCT02820454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX
Description: A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
Study NCT01037946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
Study NCT00571129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCR with no tubes or mitomycin
Description: The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR
Study NCT02820454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy
Description: 30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
Study NCT03709004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: Pacifier given to mom.
Study NCT00554450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily
Study NCT02340065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard colonoscopy
Description: examination of the colon with a conventional colonoscope
Study NCT02340065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff-assisted colonoscopy
Description: examination of the colon with Endocuff-assisted colonoscopy
Study NCT02223338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
Study NCT02223338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Aseptic Technique
Description: Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
Study NCT02525588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CS fixed bearing total knee prosthesis
Description: The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
Study NCT03691597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: improved patient satisfaction ,marginal integrity, shade match and gingival health
Description: For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G
Study NCT03691597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: improved patient satisfaction ,marginal integrity, shade match and gingival health
Description: For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G
Study NCT04870502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG
Description: In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
Study NCT04401891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal pre-operative education
Description: One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
Study NCT04429191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Description: Procedure: single intravenous infusion of JSP191 antibody
Study NCT01751009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements
Description: Sprinkles with Vitamin A
Study NCT01458327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: 125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
Study NCT01458327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy
Study NCT00287768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + S-1
Description: Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
Study NCT00287768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 po days 1-28 every 6 weeks
Study NCT01751009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles without Vitamin A
Description: Active comparator
Study NCT00352001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Study NCT00352001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Study NCT03066193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol and Palmitoylethanolamide
Description: Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
Study NCT01243723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eductyl suppository
Description: One suppository every morning during 21 days
Study NCT01243723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Description: One suppository every morning during 21 days
Study NCT02118974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy
Study NCT03331900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR388
Description: Administered as oral capsule
Study NCT03331900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as oral capsule
Study NCT03415282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% topical ointment
Description: RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
Study NCT05659823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl-morphine elective group
Description: Guideline recommended analgesia in elective caesarian section.
Study NCT05659823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl elective group
Description: Current analgesia in elective caesarian section.
Study NCT05659823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl emergency group
Description: Current analgesia in emergency caesarian section.
Study NCT02318966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medical Food - Glycosade
Description: double blind randomised crossover of 2 starches - glycosade and UCCS
Study NCT02318966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medical Food - Glycosade
Description: double blind randomised crossover of 2 starches - glycosade and UCCS
Study NCT03094741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CancerLife
Description: CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
Study NCT00718510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: 3 grams, twice daily, oral administration
Study NCT00718510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Arginine
Description: 3 grams, twice daily, oral administration
Study NCT03170700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program with in-person parental feeding content
Description: Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
Study NCT00694980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Intravenous and subcutaneous escalating doses
Study NCT00694980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuMAb Beta7
Description: Intravenous and subcutaneous escalating doses
Study NCT00655564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose).
Study NCT01166308 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
Study NCT01166308 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Stereotactic Radiotherapy (FSRT)
Description: Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
Study NCT03252236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Modified 12-form Yang style Tai Chi.
Study NCT03252236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
Study NCT04559802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmucosal Technique
Description: Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
Study NCT04559802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submerged Technique
Description: Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
Study NCT02463604 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary Angiography
Description: Coronary angiography is performed following usual site standards
Study NCT02463604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography
Description: Coronary angiography is performed following usual site standards